Sir Run Run Shaw Hospital
- Country
- People's Republic of China
- Ownership
- Private
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
103
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (82 trials with phase data)• Click on a phase to view related trials
The Impact of Intelligent Nursing Based on Health Cloud Platform on Active Health Management of Urostomy Patients
- Conditions
- Urinary Bladder Neoplasms
- First Posted Date
- 2025-10-01
- Last Posted Date
- 2025-10-01
- Lead Sponsor
- Sir Run Run Shaw Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT07201441
- Locations
- 🇨🇳
Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
The Efficacy and Safety of Neoadjuvant Therapy With Iparomlimab and Tuvonralimab in Locally Advanced MSI-H/dMMR Colorectal Cancer: An Prospective, Single-Arm Study (Neo-IT)
- Conditions
- dMMR/MSI-H-type Rectal Adenocarcinoma
- Interventions
- Drug: Ipalolimab and Tovorilimab
- First Posted Date
- 2025-09-08
- Last Posted Date
- 2025-09-08
- Lead Sponsor
- Sir Run Run Shaw Hospital
- Target Recruit Count
- 29
- Registration Number
- NCT07160647
- Locations
- 🇨🇳
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine,, Hangzhou, Zhejiang, China
Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma
- Conditions
- Cholangiocarcinoma
- Interventions
- Drug: Sacituzumab tirumotecan (iv)+Putolizumab injection (iv)
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-06
- Lead Sponsor
- Sir Run Run Shaw Hospital
- Target Recruit Count
- 59
- Registration Number
- NCT07105852
- Locations
- 🇨🇳
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine (Qingchun Campus) 3 Qingchun Road East, Shangcheng District, Hangzhou, Zhejiang, China, Hangzhou, Zhejiang, China
Node-Sparing Short-Course Radiation Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Rectal Cancer
- Conditions
- Rectal Cancer
- Interventions
- Radiation: Lymph-node-sparing short-course radiotherapyDrug: PD-1/CTLA-4 inhibitor (Aiparolitoworixureli injection)
- First Posted Date
- 2025-07-16
- Last Posted Date
- 2025-07-30
- Lead Sponsor
- Sir Run Run Shaw Hospital
- Target Recruit Count
- 52
- Registration Number
- NCT07068763
Early Endovascular Treatment in Isolated Internal Carotid Artery Occlusion
- Conditions
- Stroke, Acute Ischemic
- Interventions
- Procedure: Endovascular treatmentDrug: The best medical treatment
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Sir Run Run Shaw Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT07016854
- Locations
- 🇨🇳
Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 20
- Next
News
Chinese Scientists Develop Revolutionary 'Bone-02' Adhesive That Heals Fractures in Three Minutes
Chinese researchers have developed "Bone-02," a medical adhesive inspired by oyster biology that can repair fractures and shattered bones in just two to three minutes.
Tenecteplase Investigated for Preventing Myocardial Infarction Post-PCI
A randomized controlled trial is set to evaluate intracoronary tenecteplase (TNK) for preventing periprocedural myocardial infarction (PMI) in CAD patients undergoing PCI.